Abstract
Background The emergence of polymyxin resistance, due to transferable mcr-genes, threatens public and animal health as there are limited therapeutic options. As polymyxin is one of the last-line antibiotics, there is a need to contain the spread of its resistance to conserve its efficacy. Herein, we describe current and emerging polymyxin resistance diagnostics to inform faster clinical diagnostic choices.
Methods A literature search in diverse databases for studies published between 2016 and 2020 was performed. English articles evaluating colistin resistance methods/diagnostics were included.
Results Screening resulted in the inclusion of 93 journal articles. Current colistin resistance diagnostics are either phenotypic or molecular. Broth microdilution (BMD) is currently the only gold standard for determining colistin MICs (minimum inhibitory concentration).
Phenotypic methods comprise of agar-based methods such as CHROMagar™ Col-APSE, SuperPolymyxin, ChromID® Colistin R, LBJMR, and LB medium; manual MIC-determiners viz., UMIC, MICRONAUT MIC-Strip (MMS), and ComASP Colistin; automated antimicrobial susceptibility testing (AST) systems such as BD Phoenix, MICRONAUT-S, MicroScan, Sensititre and Vitek 2; MCR-detectors such as lateral flow immunoassay (LFI) and chelator-based assays including EDTA- and DPA-based tests i.e. combined disk test (CDT), modified colistin broth-disk elution (CBDE), Colispot, and Colistin MAC test as well as biochemical colorimetric tests i.e. Rapid Polymyxin NP test and Rapid ResaPolymyxin NP test. Molecular methods only characterize mobile colistin resistance; they include PCR, LAMP, and whole-genome sequencing (WGS).
Conclusion Due to the faster turnaround time (≤3h), improved sensitivity (84-100%), and specificity (93.3-100%) of the Rapid ResaPolymyxin NP test, we recommend this test for initial screening of colistin-resistant isolates. This can be followed by CBDE with EDTA or the LFI as they both have 100% sensitivity and a specificity of ≥ 94.3% for the rapid screening of mcr-genes. However, molecular assays such as LAMP and PCR may be considered in well-equipped clinical laboratories.
Author summary/highlights/importance
Polymyxin resistance is rapidly increasing, threatening public and veterinary healthcare.
As one of the last-line antibiotics, polymyxin must be conserved by containing the spread of polymyxin resistance.
Detecting colistin resistance relies on determining colistin MIC values by standard broth microdilution, which is labour-intensive with longer turnaround time (TAT).
Other polymyxin resistance diagnostics have been developed to augment or replace the broth microdilution with faster TAT.
Based on their respective sensitivities, specificities, TAT, skill, and cost, selected phenotypic and molecular assays are recommended for laboratories, according to their financial strengths, to enhance colistin resistance surveillance and control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Tweet: “Colistin resistance is a global threat to bacterial infections’ management. Being a last- resort antibiotic for treating of MDR Gram-negative infections, it is important to establish an efficient diagnostic method for routine use in clinical microbiology laboratories. Herein, current & emerging diagnostics for detecting colistin resistance are described to inform clinical diagnostic options.”
This version has been revised to remove certain literary errors, clarification of the nature of the Sensititre test, and better formatting of the Table
Data Availability
All data are available in the manuscript
